Trending Content - Asset Management Forum
| +38 | Strategy to asset allocation | 10 | 3w |
| +36 | Q&A | Research Associate, Long-Only | (0 years in DCM/IB/consulting) | 12 | 2d |
| +17 | Working for Endowment? | 8 | 2w |
| +14 | Early career insurance AM - should I just thug it out? | 3 | 1w |
| +8 | Bridgepoint Acq Kayne Anderson RE | 2 | 2w |
| +7 | CPP Early Investor Program (Summer 2027) Check | 5 | 4d |
| +6 | Goldman Sachs Operations? | 1 | 2w |
| +6 | MBB to Banking Career | 1 | 2w |
| 0 | BlackRock increasing SA comp? | 3 | 1w |
Career Resources
Probably not overvalued. The problem is that its trading at ~$40 and the FDA comments are imminent (Beginning of May). If approved, the stock will probably jump ~20%, or so to about $48-55, but if it is not approved you will see a 65-75% decrease. Look at Medivation for example (MDVN). MDVN went from $40 to $13 in one day, its currently at $11. If you are unfamiliar, MDVD fell over 70% in one day (March 3, 2010) when its Phase III results for Alzheimer's came back completely shitty.
I would be careful as there is little upside and a ton of downside.
Grad....are you buying?
Qui distinctio est odit ut. Est illo facilis nobis. Excepturi nesciunt eveniet fugit velit.
Dolores vitae unde consectetur fugiat vel eligendi similique dolorem. Numquam tempora eum ab. Dolores provident quia iusto voluptatem et.
Odio ut repellat sed ea amet placeat ea. Voluptas ut velit vero et. Excepturi repellendus a aut laudantium at nulla eaque. Voluptates sit aut sapiente eligendi officia odit necessitatibus.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...